HemaCell
company
About
HemaCell is a new cell therapy company to regenerate hematopoietic lineages in vitro, with unique stem cell reprogramming.
- Suzhou,Jiangsu,China
Details
- Last Funding Type
- Series A
- Industries
- Biotechnology,Pharmaceutical
- Founded date
- Jun 1, 2021
- Operating Status
- Active
- Legal Name
- Suzhou Xueji Biotechnology Co., Ltd.
- Also Known As
- Xueji Bio
Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish a platform using platelet cells as a drug delivery carrier.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
¥100M
HemaCell has raised a total of
¥100M
in funding over 2 rounds. Their latest funding was raised on
May 27, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 27, 2022 | Series A | — | 7 | — | — | Detail |
| Feb 25, 2022 | Seed | ¥100M | 8 |
CMB International Capital Corporation
Northern Light Venture Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
14
HemaCell is funded by 14 investors.
CMB International Capital Corporation
and Northern Light Venture Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
CMB International Capital Corporation
|
Yes | Seed |
|
Northern Light Venture Capital
|
Yes | Seed |
|
|
— | Series A |
|
|
— | Series A |
Country Garden Venture Capital
|
— | Series A |
Founder H Fund
|
— | Series A |
Laurel Venture Capital
|
— | Series A |
Lucion
|
— | Series A |
WeDo Capital Management
|
— | Series A |
|
|
— | Seed |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
